Showing 1 - 20 results of 52 for search 'Jin-Yuan Shih', query time: 0.09s Refine Results
  1. 1
    The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer

    The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer by Yen-Ting Lin, Yen-Ting Lin, Yi-Nan Liu, Jin-Yuan Shih, Jin-Yuan Shih

    Published 2019-09-01
    Get full text
    Article
  2. 2
    Time to be familiar with nontuberculous mycobacterial lung disease - An emerging disease with diverse clinical outcomes

    Time to be familiar with nontuberculous mycobacterial lung disease - An emerging disease with diverse clinical outcomes by Jann-Yuan Wang, Jin-Yuan Shih, Meng-Chih Lin

    Published 2020-06-01
    Get full text
    Article
  3. 3
    Primary resistance to osimertinib despite acquired T790M

    Primary resistance to osimertinib despite acquired T790M by Ling‐Kai Chang, Yih‐Leong Chang, Jin‐Yuan Shih

    Published 2020-03-01
    Get full text
    Article
  4. 4
    Association of pulmonary nontuberculous mycobacteria with the outcomes of patients with lung cancer: A retrospective matched cohort study with a special emphasis on the impact of chemotherapy

    Association of pulmonary nontuberculous mycobacteria with the outcomes of patients with lung cancer: A retrospective matched cohort study with a special emphasis on the impact of c... by Ting-Yu Liao, Jann-Yuan Wang, Jin-Yuan Shih

    Published 2023-04-01
    Get full text
    Article
  5. 5
    A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non‐small‐cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor

    A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non‐small‐cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase... by Lun‐Che Chen, Jin‐Yuan Shih, Chong‐Jen Yu, Ching‐Yao Yang

    Published 2019-07-01
    Get full text
    Article
  6. 6
    Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation

    Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation by I-Hsien Lee, Ching-Yao Yang, Jin-Yuan Shih, Chong-Jen Yu

    Published 2021-10-01
    Get full text
    Article
  7. 7
    Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer

    Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer by Chung-Yu Chen, Kuan-Yu Chen, Jin-Yuan Shih, Chong-Jen Yu

    Published 2020-10-01
    Get full text
    Article
  8. 8
    Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.

    Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R. by Chien-Hung Gow, Jin-Yuan Shih, Yih-Leong Chang, Chong-Jen Yu

    Published 2005-09-01
    Get full text
    Article
  9. 9
    The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation

    The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation by Shang-Gin Wu, Chong-Jen Yu, James Chih-Hsin Yang, Jin-Yuan Shih

    Published 2020-08-01
    Get full text
    Article
  10. 10
    Treating patients with -positive non-small cell lung cancer: latest evidence and management strategy

    Treating patients with -positive non-small cell lung cancer: latest evidence and management strategy by Bin-Chi Liao, Chia-Chi Lin, Jin-Yuan Shih, James Chih-Hsin Yang

    Published 2015-09-01
    Get full text
    Article
  11. 11
    Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study

    Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study by Chien-Hung Gow, Chien-Hung Gow, Chien-Hung Gow, Min-Shu Hsieh, Yi-Lin Chen, Yi-Nan Liu, Shang-Gin Wu, Shang-Gin Wu, Jin-Yuan Shih, Jin-Yuan Shih

    Published 2023-03-01
    Get full text
    Article
  12. 12
    Cytologically Proven Meningeal Carcinomatosis in Patients with Lung Cancer: Clinical Observation of 34 Cases

    Cytologically Proven Meningeal Carcinomatosis in Patients with Lung Cancer: Clinical Observation of 34 Cases by Tzu-Yi Chuang, Chong-Jen Yu, Jin-Yuan Shih, Pan-Chyr Yang, Sow-Hsong Kuo

    Published 2008-11-01
    Get full text
    Article
  13. 13
    Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors

    Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors by Shang-Gin Wu, Yih-Leong Chang, Chong-Jen Yu, Pan-Chyr Yang, Jin-Yuan Shih

    Published 2017-07-01
    Get full text
    Article
  14. 14
    Lung adenocarcinoma with neuroendocrine differentiation: Molecular markers testing and treatment outcomes

    Lung adenocarcinoma with neuroendocrine differentiation: Molecular markers testing and treatment outcomes by Hao-Chun Chang, Kuan-Yu Chen, Yih-Leong Chang, Jin-Yuan Shih, Chong-Jen Yu

    Published 2023-08-01
    Get full text
    Article
  15. 15
    Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study

    Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study by Yung-Hsuan Chen, Yen-Fu Chen, Chung-Yu Chen, Jin-Yuan Shih, Chong-Jen Yu

    Published 2019-10-01
    Get full text
    Article
  16. 16
    Differences in Fatty Acid Oxidation between Nab-Paclitaxel- and Solvent-Based Paclitaxel-Treated A549 Cells Based on Metabolomics

    Differences in Fatty Acid Oxidation between Nab-Paclitaxel- and Solvent-Based Paclitaxel-Treated A549 Cells Based on Metabolomics by Jhih-Wei Huang, Ching-Hua Kuo, Han-Chun Kuo, Jin-Yuan Shih, Teng-Wen Tsai, Lin-Chau Chang

    Published 2021-02-01
    Get full text
    Article
  17. 17
    Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel.

    Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel. by Jhih-Wei Huang, Ching-Hua Kuo, Han-Chun Kuo, Jin-Yuan Shih, Teng-Wen Tsai, Lin-Chau Chang

    Published 2021-01-01
    Get full text
    Article
  18. 18
    Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer

    Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer by Yu-Sen Huang, Jenny Ling-Yu Chen, Hsin-Ming Chen, Li-Hao Yeh, Jin-Yuan Shih, Ruoh-Fang Yen, Yeun-Chung Chang

    Published 2021-04-01
    Get full text
    Article
  19. 19
    miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44

    miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44 by Shang-Gin Wu, Tzu-Hua Chang, Meng-Feng Tsai, Yi-Nan Liu, Yen-Lin Huang, Chia-Lang Hsu, Han-Nian Jheng, Jin-Yuan Shih

    Published 2024-03-01
    Get full text
    Article
  20. 20
    miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway

    miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway by Yi-Nan Liu, Meng-Feng Tsai, Shang-Gin Wu, Tzu-Hua Chang, Tzu-Hsiu Tsai, Chien-Hung Gow, Hsin-Yi Wang, Jin-Yuan Shih

    Published 2020-12-01
    Get full text
    Article

Search Tools: